Clinical trials: PSMA PET
Prostate Cancer
Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
This is a study primarily comparing Magnetic Resonance Imaging (MRI) alone to Positron Emission Tomography (PET)/MRI using an experimental tracer, 68Ga-PSMA-HBED-CC, among men with prostate cancer or prostatic cancer…
- Trial name
- NCT03439033
- Testing
- PET/MRI with Gallium-68 labeled PSMA-HBED-CC, Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC, PET/CT with Gallium-68 labeled PSMA-HBED-CC
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- Weill Medical College of Cornell University
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate…
- Trial name
- SABRE (NCT05407311)
- Testing
- 64Cu-SAR-BBN
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
The overall objective of this Early Phase Clinical Trial is to begin defining the accuracy of 68Ga-PSMA-11 for detecting the location and size of clinically significant prostate cancer lesions in low and intermediate risk…
- Trial name
- NCT03429244
- Testing
- 68Ga-PSMA-11 PET-MRI
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Prostate Cancer
PSMA Imaging of Localized Prostate Cancer
The present study is a phase II, open label, single-center, non-randomized, single-dose study. Twenty subjects in total will be enrolled at Weill Cornell Medical College (WCMC)/ NYPH.
- Trial name
- NCT03675451
- Testing
- 89ZR-DF-IAB2M, 68Ga-PSMA-HBED-CC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
The purpose of the study is to find out whether imaging of the prostate with a new molecule called 68Ga-PSMA can find prostate cancer.
- Trial name
- NCT03689582
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
The purpose of this study was to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT).
- Trial name
- GuideView (NCT04838626)
- Testing
- [18F]CTT1057
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the…
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT05176223
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma, PSA Failure
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan.
- Conditions
- Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
- Trial name
- NCT02673151
- Testing
- Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Andrei Iagaru
Metastatic Castration-resistant Prostate Cancer
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04631601
- Testing
- Acapatamab, Enzalutamide, Abiraterone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Prostate Cancer
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy…
- Trial name
- NCT03949517
- Testing
- 68-Ga RM2, 68-Ga PSMA11, Investigational software and coils in PET/MR Scan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer, Prostatic Neoplasm
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new prostate-specific membrane antigen (PSMA) drug makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent
- Trial name
- NCT03389451
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michael Graham PhD, MD
Hepatocellular Carcinoma
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Background: A radiotracer (or tracer) is a radioactive substance. It is used in Positron Emission Tomography (PET) imaging to help see specific sites in the body.
- Trial name
- NCT05009979
- Testing
- F18-FDG, MRI, CT
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
- Trial name
- NCT03809078
- Testing
- 68Ga RM2, 68Ga-PSMA-11, Investigational PET scanner coils and software
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT03822871
- Testing
- CTT1403, CTT1057, 68Ga-PSMA-11
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cancer Targeted Technology
Prostate Adenocarcinoma, PSA Progression
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come…
- Conditions
- Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT03698370
- Testing
- Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Andrei Iagaru
Prostatic Neoplasms, Genital Neoplasms, Male
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Trial name
- NCT04461509
- Testing
- 18F-PSMA
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Alessandro D'Agnolo
Metastatic Prostate Cancer
PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study
This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at…
- Trial name
- NCT04086966
- Testing
- [68Ga]PSMA-PET/MRI or PET/CT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Alabama at Birmingham
Prostate Cancer
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand…
- Trial name
- NCT04186819
- Testing
- rhPSMA-7.3 (18F) Injection, Positron Emission Tomography scan
- Where
- 34 sites in United States, Finland and 2 more
- Volunteers
- 356 people
- Sponsor
- Blue Earth Diagnostics
Hepatocellular Carcinoma
68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
This phase II trial studies how well 68Ga-PSMA PET/MRI or PET/CT works in early detection of liver cancer. 68Gallium-PSMA is a radioactive tracer designed to circulate through the body and attach itself to the prostate- specific…
- Trial name
- NCT04762888
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic